Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus W Thomson

Showing results (151-160 of 249) with videos related to

Pageof 25
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 31, 2012
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cellsSiddharth Jhunjhunwala, Stephen C Balmert, Giorgio Raimondi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2006
"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-IgYuk Yuen Lan, Zhiliang Wang, Giorgio Raimondi, et al.
Oncoimmunology|July 30, 2016
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responsesDàlia Raïch-Regué, Kellsye P Fabian, Alicia R Watson, et al.
Hepatology (Baltimore, Md.)|July 2, 2013
CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in miceOsamu Yoshida, Shoko Kimura, Edwin K Jackson, et al.
Blood|January 18, 2003
Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivoHolger Hackstein, Timucin Taner, Alan F Zahorchak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2015
mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In VivoDàlia Raïch-Regué, Brian R Rosborough, Alicia R Watson, et al.
Stroke|February 6, 2014
Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after strokePeiying Li, Leilei Mao, Xiangrong Liu, et al.
Transplant Immunology|February 10, 2015
CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejectionOsamu Yoshida, Lei Dou, Shoko Kimura, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 31, 2002
Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154)Holger Hackstein, Zhiliang Wang, Adrian E Morelli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipientsGiorgio Raimondi, Tina L Sumpter, Benjamin M Matta, et al.
Pageof 25

Showing results (151-160 of 249) with videos related to

Sort By:
Pageof 25
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 31, 2012
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cellsSiddharth Jhunjhunwala, Stephen C Balmert, Giorgio Raimondi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2006
"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-IgYuk Yuen Lan, Zhiliang Wang, Giorgio Raimondi, et al.
Oncoimmunology|July 30, 2016
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responsesDàlia Raïch-Regué, Kellsye P Fabian, Alicia R Watson, et al.
Hepatology (Baltimore, Md.)|July 2, 2013
CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in miceOsamu Yoshida, Shoko Kimura, Edwin K Jackson, et al.
Blood|January 18, 2003
Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivoHolger Hackstein, Timucin Taner, Alan F Zahorchak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2015
mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In VivoDàlia Raïch-Regué, Brian R Rosborough, Alicia R Watson, et al.
Stroke|February 6, 2014
Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after strokePeiying Li, Leilei Mao, Xiangrong Liu, et al.
Transplant Immunology|February 10, 2015
CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejectionOsamu Yoshida, Lei Dou, Shoko Kimura, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 31, 2002
Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154)Holger Hackstein, Zhiliang Wang, Adrian E Morelli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipientsGiorgio Raimondi, Tina L Sumpter, Benjamin M Matta, et al.
Pageof 25